Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for quality of life in heart failure with reduced ejection fraction
IRCT20250518065795N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Ivabradine plus routine treatment with Placebo plus routine treatment (2 arms). Primary endpoint: Quality of life score based on Minnesota Living with Heart Failure Questionnaire. Started Sep 2025; status: completed.
02
Drugs
ivabradine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on IRCT20250518065795N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250518065795N1.